Tarceva (erlotinib), a new ORAL treatment for non-small cell lung cancer (NSCLC)

You'll soon see Tarceva (erlotinib), a new ORAL treatment for non-small cell lung cancer (NSCLC).

It increases survival in patients with advanced NSCLC.

Think of it as similar to gefitinib (Iressa). These drugs target growth factors that stimulate tumor growth.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote